Search Result

Results for "

Dry eye disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Apoptosis (2) Biochemical Assay Reagents (2) Calcium Channel (2) Cathepsin (1) CFTR (1) Collagen (1) COX (2) ERK (2) Formyl Peptide Receptor (FPR) (1) Glucocorticoid Receptor (1) Integrin (5) Isotope-Labeled Compounds (3) JAK (1) Keap1-Nrf2 (1) NF-κB (2) P2Y Receptor (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Small Interfering RNA (siRNA) (2) TRP Channel (2)
By Research Areas:	Cancer (2) Inflammation/Immunology (15) Neurological Disease (6)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-19344

Lifitegrast Maximum Cited Publications 11 Publications Verification SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344A

Lifitegrast sodium Maximum Cited Publications 11 Publications Verification SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

HY-B0606

Diquafosol tetrasodium 5 Publications Verification INS365	P2Y Receptor	Inflammation/Immunology
Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

HY-172435

Rezuforimod AGN-232411; AG-80308; AGN-411	Formyl Peptide Receptor (FPR)	Neurological Disease
Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .

HY-132596A

Tivanisiran sodium SYL1001 sodium	Small Interfering RNA (siRNA) TRP Channel	Neurological Disease
Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease .

HY-106449

Recoflavone DA-6034 free acid	NF-κB COX Apoptosis ERK Calcium Channel	Inflammation/Immunology Cancer
Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca( ²⁺)]_i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .

HY-W143531

Perfluorohexyloctane NOV03; SHR8058	Biochemical Assay Reagents	Inflammation/Immunology
Perfluorohexyloctane (NOV03), a semifluorinated alkane, reduces tear film instability in Meibomian gland dysfunction and evaporative dry eye disease. Perfluorohexyloctane is a long-term tamponade agent. Perfluorohexyloctane increases tear film breakup time and lipid layer thickness .

HY-152264

CFTR activator 1	CFTR	Inflammation/Immunology
CFTR activator 1 is a potent and selective CFTR activator, with an EC₅₀ of 23 nM. CFTR activator 1 can be used to ameliorate dry eye disease .

HY-P10904

Vezocolmitide ST-100	Collagen	Others
Vezocolmitide (ST-100) is a collagen mimetic peptide. Vezocolmitide can rapidly repair damaged collagen triple helix structures, thereby quickly reversing damage to the ocular surface and extracellular matrix, and restoring corneal nerve function while repairing the epithelium. Vezocolmitide can be used for research of dry eye disease (DED) .

HY-132596

Tivanisiran SYL1001	Small Interfering RNA (siRNA) TRP Channel	Neurological Disease
Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .

HY-19344R

Lifitegrast (Standard) SAR 1118 (Standard); SHP-606 (Standard)	Reference Standards Integrin	Inflammation/Immunology
Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-153565

Immune cell migration-IN-1	Others	Inflammation/Immunology
Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis .

HY-154994

JAK-IN-30	JAK	Inflammation/Immunology
JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .

HY-180939

LFA-1-IN-2	Integrin	Neurological Disease Inflammation/Immunology
LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a K_d of 21.46 μM. LFA-1-IN-2 inhibits ICAM-1-mediated cell adhesion. LFA-1-IN-2 protects cells from inflammatory hyperosmotic stress. LFA-1-IN-2 improves dry eye disease .

HY-19344S2

Lifitegrast-d4-1	Isotope-Labeled Compounds Integrin	Inflammation/Immunology
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-153567

Immune cell migration-IN-2	Biochemical Assay Reagents	Inflammation/Immunology
Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC₅₀ of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106449R

Recoflavone (Standard) DA-6034 free acid (Standard)	Reference Standards NF-κB COX Apoptosis ERK Calcium Channel	Inflammation/Immunology Cancer
Recoflavone (Standard) is the analytical standard of Recoflavone (HY-106449). This product is intended for research and analytical applications. Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca(2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .

HY-171925

BI-1124	Cathepsin	Neurological Disease
BI-1124 is a cathepsin S inhibitor that exhibits simulated sufficient ocular pharmacokinetic-pharmacodynamic coverage in rabbit models via topical ocular administration. BI-1124 can be used for the research of age-related dry eye disease .

HY-19344S

Lifitegrast-d4 SAR 1118-d₄; SHP-606-d₄	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6 SAR 1118-d₆; SHP-606-d₆	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-183905

KR-67607	11β-HSD Glucocorticoid Receptor Reactive Oxygen Species (ROS) Keap1-Nrf2	Neurological Disease
KR-67607 is a selective 11β-HSD1 inhibitor, with an IC₅₀ value of 4.8 nM against h11β-HSD1 and 7.1 nM against mouse 11β-HSD1. KR-67607 inhibits stress-induced Glucocorticoid receptor nuclear translocation, reduces cortisol levels, suppresses the expression of ROS and proinflammatory cytokines, and enhances Nrf-2-mediated antioxidant gene transcription. KR-67607 maintains trabecular meshwork structure and reverses elevated intraocular pressure. KR-67607 improves ocular antioxidant activity and mucus secretion, reverses ocular surface damage, and prevents ischemia-reperfusion induced ocular injury. KR-67607 can be used in research related to glaucoma and dry eye disease .

Cat. No.	Nombre del producto	Target	Research Area

HY-P10904

Vezocolmitide ST-100	Collagen	Others
Vezocolmitide (ST-100) is a collagen mimetic peptide. Vezocolmitide can rapidly repair damaged collagen triple helix structures, thereby quickly reversing damage to the ocular surface and extracellular matrix, and restoring corneal nerve function while repairing the epithelium. Vezocolmitide can be used for research of dry eye disease (DED) .

Cat. No.	Nombre del producto	Chemical Structure

HY-19344S2

Lifitegrast-d4-1
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Cat. No.	Nombre del producto		Classification

HY-132596A

Tivanisiran sodium SYL1001 sodium		siRNAs siRNA drugs
Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease .

HY-132596

Tivanisiran SYL1001		siRNAs siRNA drugs
Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Name
E-mail *

	Sorry, but the email address you supplied was invalid.